Apixaban for the prevention of venous thromboembolism in people ...

[34] School of Health and Related Research (ScHARR). Rivaroxaban for the prevention of venous
thromboembolism [Internet]. Sheffield: ScHARR, University of Sheffield, 2009 [cited 9.9.11]
Available from: http://www.nice.org.uk/guidance/index.jsp?action=download&o=43711
[35] Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous
thromboembolism in patients undergoing elective hip and knee surgery: a single technology
appraisal [Internet]: ScHARR, University of Sheffield, 2008 [cited: 25.8.11] Available from:
http://www.hta.ac.uk/erg/reports/1719.pdf
[36] Davies LM, Richardson GA, Cohen AT. Economic evaluation of enoxaparin as postdischarge
prophylaxis for deep vein thrombosis (DVT) in elective hip surgery. Value Health
2000;3(6):397-406.
[37] Davies GC, Salzman EW. Cost effectiveness of prophylaxis of venous thromboembolism. J R
Soc Med 1981;74(3):177-80.
[38] Drummond M, Aristides M, Davies L, Forbes C. Economic evaluation of standard heparin and
enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br J Surg
1994;81(12):1742-6.
[39] Gordois A, Posnett J, Borris L, Bossuyt P, Jonsson B, Levy E, et al. The cost-effectiveness of
fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following
major orthopedic surgery. J Thromb Haemost 2003;1(10):2167-74.
[40] McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban
and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total
knee replacement in the irish healthcare setting. Pharmacoeconomics 2009;27(10):829-46.
[41] Nicolaides AN, Bosanquet N. Cost-effectiveness of desirudin in the prevention of the
thromboembolic complications of surgery. J Med Econ 1999; 2(1-4 ):155-66.
[42] Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, et al. Economic
evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee
and hip replacement surgery. Clin Ther 2009;31(1):194-212.
[43] Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Noack H, Robinson PA, et al. Economic
evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged
over 75 years or with moderate renal impairment undergoing total knee or hip replacement.
Thromb Haemost 2010;103(2):360-71.
[44] Diamantopoulos A, Forster F, Brosa M, Lees M, Gilmour L, Ashley D, et al. Cost-effectiveness
of rivaroxaban versus enoxaparin for thromboprophylaxis after total knee replacement in the UK
and Spain. ISPOR 11th Annual European Congress 2008; Poster presentations session 2 (Health
care intervention).PHC8 [As cited in the manufacturer's submission].
[45] Diamantopoulos A, Forster F, Brosa M, Lees M, Gilmour L, Ashley D, et al. Cost-effectiveness
of rivaroxaban versus enoxaparin for thromboprophylaxis after total hip replacement in the UK.
74
Copyright 2011 Queen’s Printer and Controller of HMSO. All rights reserved.